{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:33:30Z","timestamp":1788813210149,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring is recommended to guide therapy with the immunosuppressant everolimus (EVL) in solid organ transplantation to prevent rejections and to limit toxicity. For therapeutic drug monitoring, predose EVL concentrations are measured in whole blood mainly by liquid chromatography tandem mass spectrometry (LC-MS\/MS). In addition, 2 immunoassays [Quantitative Microsphere System (QMS) EVL and Elecsys EVL] are commercially available. The aim of this study was to evaluate the comparability of EVL results determined with the 2 immunoassays and a validated LC-MS\/MS test using samples from kidney, liver, and heart transplant (KT, LT, and HT, respectively) recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Analysis of predose samples from KT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 56), LT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 60), and HT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 59) recipients, obtained at variable time points after transplantation, was performed by LC-MS\/MS and with the 2 immunoassays. The QMS EVL assay was applied on Dimension Xpand Plus and the Elecsys EVL assay on cobas e 411 analyzer. Results were compared by the Spearman's rank correlation coefficient, unbiased Passing and Bablok linear regression test, and Bland\u2013Altman plot.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Results generated with both immunoassays correlated well with those of LC-MS\/MS. An overestimation of EVL concentrations by the Elecsys EVL compared with LC-MS\/MS was observed (mean bias: 34.2%). Using the QMS EVL, a small but significant negative deviation (mean bias: \u22128.0%) was found. Looking at KT, HT, and LT samples separately, the bias to LC-MS\/MS seen with the Elecsys EVL was similar. With the QMS EVL, the best agreement was observed with the KT samples followed by LT and HT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Results generated by the 3 methods are not consistent regarding their diagnostic value. Both laboratories and manufacturers should take care to inform their costumers about the between-method differences to avoid misinterpretation of the results in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000376","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T18:27:12Z","timestamp":1485368832000},"page":"102-108","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method"],"prefix":"10.1097","volume":"39","author":[{"given":"Maria","family":"Shipkova","sequence":"first","affiliation":[{"name":"Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Rapp","sequence":"additional","affiliation":[{"name":"Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fcl","family":"Rigo-Bonnin","sequence":"additional","affiliation":[{"name":"Laboratori Cl\u00ednic Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Wieland","sequence":"additional","affiliation":[{"name":"Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine IV, University of Tuebingen, Tuebingen, Germany;"},{"name":"Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, University of Tuebingen, Tuebingen, Germany; and"},{"name":"German Center for Diabetes Research (DZD), Muenchen, Neuherberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/FTD.0000000000000205","article-title":"Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs","volume":"37","author":"Christians","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/FTD.0b013e31820afc97","article-title":"Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatography\/mass spectrometry","volume":"33","author":"Dasgupta","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","first-page":"542","article-title":"Application of new QMS everolimus assay performed on CDx 90 analyzer (ThermoFisher) to therapeutic drug monitoring in transplant patients","volume":"33","author":"Kunicki","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R9-20230814","first-page":"542","article-title":"Evaluation of Thermo scientific QMS everolimus immunoassay reagent","volume":"33","author":"Smith","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/FTD.0b013e3182a3b3f6","article-title":"Analytical performance of QMS everolimus assay on ortho Vitros 5,1 FS fusion analyzer: measuring everolimus trough levels for solid organ transplant recipients","volume":"36","author":"Shu","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FTD.0000000000000057","article-title":"Latex-enhanced turbidimetric immunoassay for everolimus in whole blood using the Nanopia TDM everolimus assay with the JCA-BM6010 automatic analyzer","volume":"36","author":"Mori","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0000000000000133","article-title":"Evaluation of QMS everolimus assay using Indiko analyzer: comparison with an ultra-performance liquid chromatography tandem mass spectrometry (UPLC\/MS\/MS) method","volume":"37","author":"Buthiau","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/FTD.0000000000000191","article-title":"Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study","volume":"37","author":"Schniedewind","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0000000000000126","article-title":"Comparison of everolimus QMS immunoassay on Architect ci4100 and liquid chromatography\/mass spectrometry: lack of agreement in organ transplanted patients","volume":"37","author":"Hoffer","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1515\/cclm-2015-0519","article-title":"Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS\/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood","volume":"54","author":"Valbuena","year":"2016","journal-title":"Clin Chem Lab Med."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201704000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:04:52Z","timestamp":1692036292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201704000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000376","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}